ReTune Study
/ hīpō • Gōna • dizəm /
Commonly referred to “Low Testosterone” or “Testosterone Deficiency”, this disease has a profound impact on the lives of men of all ages who present symptoms such erectile dysfunction, depression, fatigue, anemia, increased body fat and more. Male hypogonadism affects 15 million in the US alone.
At Marius, we continue to research and investigate the vital role testosterone plays in all of these functions and more in order to make sure those afflicted can live their best possible lives.
The ReTUne Study is our pivotal Phase 3 study with a main study and extension study measuring the efficacy and safety of our proprietary Oral Testosterone for primary and secondary hypogonadism in males aged 18-65. From a design perspective, one of the most comprehensive trials to date, we tested 295 patients across 6 and 12 month studies and some patients had a total of 18 months of exposure to the drug. We have tested for exploratory endpoints including Patient Reported Outcomes and other important biomarkers. This study was successfully completed in 2019.
The proposed indications for Kyzatrex demonstrated through the study are:
- Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
- Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range.
Comorbidity Rate with Testosterone Deficiency
Formulation Innovation
Lymphatic Absorption
